Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 7:12:891619.
doi: 10.3389/fonc.2022.891619. eCollection 2022.

Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study

Jiayi Zhang  1 , Gang Wu  2 , Hailong Zhu  2 , Fengyuan Yang  2 , Shuman Yang  3 , Ann M Vuong  4 , Jincheng Li  2 , Demiao Zhu  2 , Yiyan Sun  2 , Wei Tao  2
Affiliations

Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study

Jiayi Zhang et al. Front Oncol. .

Abstract

Introduction: Epidemiological studies investigating the association between carnitine and breast cancer are scarce.

Materials and methods: This 1:1 age-matched retrospective case-control study identified 991 female breast cancer cases and 991 female controls without breast cancer using pathological testing. We used targeted metabolomics technology to measure 16 types of whole blood carnitine compounds, such as free carnitine (C0) and octadecanoylcarnitine (C18).

Results: The average age for cases and controls was approximately 50 ± 8.7 years. After adjusting for covariates, each standard deviation (SD) increase in malonylcarnitine (C3DC; OR 0.91; 95% CI 0.83-1.00), decenoylcarnitine (C10:1; OR 0.87; 95% CI 0.79-0.96), and decadienoylcarnitine (C10:2; OR 0.90; 95% CI 0.82-0.99) level was associated with decreased odds of breast cancer. However, higher butyrylcarnitine (C4) levels were associated with increased odds of breast cancer (OR 1.12; 95% CI 1.02-1.23). No statistically significant relationship was noted between other carnitine compounds and breast cancer. The false discovery rates for C3DC, C4, C10:1 and C10:2 were 0.172, 0.120, 0.064 and 0.139, respectively.

Conclusions: Higher levels of C3DC, C10:1, and C10:2 were protective factors for breast cancer, whereas increased C4 levels were a risk factor for the disease.

Keywords: breast cancer; carnitine; metabolites; risk assessment; women.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Association between malonylcarnitine (C3DC; per 1-SD increase) and breast cancer by pathological stage of diagnosis, tumor grade, and surrogate subtype. aAll models were adjusted for age, body mass index, age at menarche, hypertension diagnosis, type 2 diabetes diagnosis, history of cancer, smoking status, alcohol consumption, family history of cancer, postmenopausal status, and parity. Luminal B-like included HER2-positive and negative. Bold values are statistically significant at α = 0.05.
Figure 2
Figure 2
Association between butyrylcarnitine (C4; per 1-SD increase) and breast cancer by pathological stage of diagnosis, tumor grade, and surrogate subtype. aAll models were adjusted for age, body mass index, age at menarche, hypertension diagnosis, type 2 diabetes diagnosis, history of cancer, smoking status, alcohol consumption, family history of cancer, postmenopausal status, and parity. Luminal B-like included HER2-positive and negative. Bold values are statistically significant at α = 0.05.
Figure 3
Figure 3
Association between decenoylcarnitine (C10:1; per 1-SD increase) and breast cancer by pathological stage of diagnosis, tumor grade, and surrogate subtype. aAll models were adjusted for age, body mass index, age at menarche, hypertension diagnosis, type 2 diabetes diagnosis, history of cancer, smoking status, alcohol consumption, family history of cancer, postmenopausal status, and parity. Luminal B-like included HER2-positive and negative. Bold values are statistically significant at α = 0.05.
Figure 4
Figure 4
Association between decadienoylcarnitine (C10:2; per 1-SD increase) and breast cancer by pathological stage of diagnosis, tumor grade, and surrogate subtype. aAll models were adjusted for age, body mass index, age at menarche, hypertension diagnosis, type 2 diabetes diagnosis, history of cancer, smoking status, alcohol consumption, family history of cancer, postmenopausal status, and parity. Luminal B-like included HER2-positive and negative. Bold values are statistically significant at α = 0.05.
See this image and copyright information in PMC

References

    1. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. . Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer (2020) 126(20):2225–49. doi: 10.1002/cncr.32802 - DOI - PMC - PubMed
    1. Jia M, Zheng R, Zhang S, Zeng H, Zou X, Chen W. Female Breast Cancer Incidence and Mortality in 2011, China. J Thorac Dis (2015) 7(7):1221–6. doi: 10.3978/j.issn.2072-1439.2015.05.15 - DOI - PMC - PubMed
    1. Ziegler RG, Anderson WF, Gail MH. Increasing Breast Cancer Incidence in China: The Numbers Add Up. J Natl Cancer Inst (2008) 100(19):1339–41. doi: 10.1093/jnci/djn330 - DOI - PubMed
    1. Unger-Saldana K. Challenges to the Early Diagnosis and Treatment of Breast Cancer in Developing Countries. World J Clin Oncol (2014) 5(3):465–77. doi: 10.5306/wjco.v5.i3.465 - DOI - PMC - PubMed
    1. Borgquist S, Hall P, Lipkus I, Garber JE. Towards Prevention of Breast Cancer: What Are the Clinical Challenges? Cancer Prev Res (Phila) (2018) 11(5):255–64. doi: 10.1158/1940-6207.CAPR-16-0254 - DOI - PubMed